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Abstract
Background:  Pancreatic adenosquamous carcinoma (ASC) is a rare pancreatic malignancy
subtype. We investigated the clinicopathological features and outcome of pancreatic ASC patients
after surgery.
Methods: The medical records of 12 patients with pancreatic ASC undergoing surgical treatment
(1993 to 2006) were retrospectively reviewed. Survival data of patients with stage IIB pancreatic
adenocarcinoma and ASC undergoing surgical resection were compared.
Results: Symptoms included abdominal pain (91.7%), body weight loss (83.3%), anorexia (41.7%)
and jaundice (25.0%). Tumors were located at pancreatic head in 5 (41.7%) patients, tail in 5
(41.7%), and body in 4 (33.3%). Median tumor size was 6.3 cm. Surgical resection was performed
on 7 patients, bypass surgery on 3, and exploratory laparotomy with biopsy on 2. No surgical
mortality was identified. Seven (58.3%) and 11 (91.7%) patients died within 6 and 12 months of
operation, respectively. Median survival of 12 patients was 4.41 months. Seven patients receiving
surgical resection had median survival of 6.51 months. Patients with stage IIB pancreatic ASC had
shorter median survival compared to those with adenocarcinoma.
Conclusion: Aggressive surgical management does not appear effective in treating pancreatic ASC
patients. Strategies involving non-surgical treatment such as chemotherapy, radiotherapy or target
agents should be tested.
Background
Adenocarcinoma accounts for the majority of pancreatic
malignancies. Adenosquamous carcinoma (ASC) of the
pancreas is an unusual variant of pancreatic neoplasm [1-
4], and is characteristic by histological patterns of both
ductal adenocarcinoma and squamous carcinoma within
the same tumor. The prognosis of this rare tumor appears
to be even less favorable than the common invasive ductal
tumor with few patients surviving more than 1 year after
surgical resection [4]. Most of studies on this disease have
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been small series or single case reports, and few studies
have investigated the clinicopathologic features and out-
come of patients with pancreatic ASC following surgical
treatment [1,2,5,6]. Therefore, medical records of 12
patients with pancreatic ASC treated surgically at Chang
Gung Memorial Hospital (CGMH), Taoyuan in the past
14 years were retrospectively reviewed.
Methods
A total of 637 patients with pancreatic malignancies
underwent surgical treatment at CGMH between January
1993 and December 2006. Adenocarcinoma was diag-
nosed in 530 patients and ASC in 12. Institutional Review
Board approval was obtained and medical records of 12
patients with pancreatic ASC were retrospectively
reviewed. Preoperative imaging studies employed abdom-
inal ultrasonography, abdominal computed tomography
(CT)/magnetic resonance imaging (MRI), and endoscopic
retrograde cholangiopancreatography (ERCP). Serum
tumor markers such as carcinoembryonic antigen (CEA)
and carbohydrate antigen 19-9 (CA 19-9) were measured
preoperatively. One patient had a preoperative fine needle
tumor biopsy. Intraoperative radiotherapy and postoper-
ative chemotherapy were performed in 2 patients and 7
patients, respectively. Tumor stage and TMN stage were
defined according to the sixth edition of American Joint
Committee on Cancer for pancreatic carcinoma [7] based
on the histopathologic examination of surgical specimens
and clinical findings such as imaging studies and intraop-
erative records. To further elucidate the outcome follow-
ing surgical resection for pancreatic ASC from more
common pancreatic adenocarcinoma, patients with stage
IIB pancreatic adenocarcinoma undergoing surgical resec-
tion were also extracted from our databank (at the same
studying period as pancreatic ASC). Survival data of
patients with stage IIB pancreatic adenocarcinoma and
ASC undergoing surgical resection were compared. Sur-
vival rate was calculated and graphs plotted using Kaplan-
Meier method. Differences in survival curves between the
groups were compared by the log-rank test. A p-value less
than 0.05 were defined as statistically significant. All sta-
tistical analyses were performed with SPSS for Windows,
version 11.5 (Statistical Package for the Social Science,
SPSS, Inc., Chicago, Illinois).
Results
The demographic features of 12 patients with pancreatic
ASC including 5 men and 7 women (age range, 32 to 79
years; median, 71 years) are shown in Table 1. Symptoms
were abdominal pain in 11 patients (91.7%), body weight
loss in 10 (83.3%), anorexia in 5 (41.7%), jaundice in 3
(25.0%). Ten patients had 13 comorbidities including
hypertension in 5, diabetes mellitus in 4 and peptic ulcer
in 3, and heart disease in 1. Laboratory studies revealed
anemia in 9 patients (75.0%), elevated total bilirubin lev-
els in 3 (25.0%), and elevated alkaline phosphatase levels
in 3 (25.0%). Elevated serum CEA levels and CA 19-9 lev-
els were identified in 10 patients (83.3%), respectively.
Three patients underwent ERCP, which identified tumor
obstruction of the pancreatic head duct. All patients
underwent abdominal CT or MRI, which accurately deter-
mined and localized a pancreatic tumor.
Table 2 demonstrates the details of tumor characteristics,
management and prognosis of 12 patients with pancreatic
ASC. The tumors were located at pancreatic head in 5
(41.7%) patients, tail in 5 (41.7%), and body in 4
(33.3%). Tumor size ranged from 3.5 to 8 cm with a
median of 6.3 cm. The lesions from the resected speci-
mens were firm with light tan to yellowish colors and had
Table 1: Demographics of 12 patients with pancreatic adenosquamous carcinoma.
Case Age/sex Symptoms Comorbidity Laboratory data Tumor markers
Hb
(g/dL)
Bil (T)
(mg/dL)
Alk-P
(U/L)
CEA (ng/mL) CA 19-9 (U/mL)
1 73/F Abd pain, BWL, jaundice HTN 10.4 15.7 258 262 240
2 66/M BWL, jaundice, anorexia DM 10.2 14.8 438 13.1 >240
3 65/F Abd pain, BWL, diarrhea HTN, heart disease 13.4 0.4 89 25.2 15.7
4 63/M Abd pain, BWL Peptic ulcer 13.2 0.5 92 10.2 135
5 78/M Abd pain, anorexia Nil 10.6 0.7 78 12.4 142.4
6 79/M Abd pain, BWL, anorexia, abd mass Nil 12.6 0.5 95 17.6 8.5
7 38/F Abd pain, BWL, jaundice DM 10.7 23.2 192 14.5 138
8 79/F Abd pain, dizziness, malaise HTN, DM, Peptic ulcer 7.0 0.8 59 2300 >240
9 76/F Abd pain, BWL HTN 11.3 0.5 93 5.34 129
10 32/M Abd pain, BWL Peptic ulcer 15.2 0.5 84 1.79 84
11 69/F Abd pain, BWL, anorexia DM 9.4 0.5 66 83.74 >240
12 78/F Abd pain, BWL, anorexia, malaise HTN 10.6 0.3 68 0.57 160.9
Abd, abdominal; Alk-P, alkaline phosphatase; Bil (T): total bilirubin; BWL, body weight loss; CA19-9, carbohydrate antigen 19-9 (< 37 U/mL); CEA, 
carcinoembryonic antigen (< 5 ng/mL); DM, diabetes mellitus; Hb, hemoglobin; HTN, hypertension.World Journal of Surgical Oncology 2008, 6:95 http://www.wjso.com/content/6/1/95
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merged imperceptibly with the surrounding pancreatic
parenchyma. Histologically, tumors were a mixture com-
ponent of adenocarcinoma and squamous cell carcinoma
(Figure 1). The rates of squamous component in the
tumor tissue ranged from 40 to 90% in patients undergo-
ing surgical resection. Lymph node metastases were iden-
tified in 11 patients (91.7%). Encasement of superior
mesenteric artery by the tumor was found during opera-
tion in 5 patients, and carcinomatosis in 1 patient. Surgi-
cal resection including pancreaticoduodenectomy (PD)
and subtotal or distal pacreatectomy along with total gas-
trectomy or splenectomy was performed in 7 patients. R0
(radical) resection was identified in 5 patients and R1
resection in 2 (cases 9 and 11). Five patients underwent
laparotomy followed by intra-operative biopsy of the pan-
creatic tumor and three received bypass surgery. Intraop-
erative irradiation and postoperative chemotherapy were
carried out in 2 and 7 patients, respectively. Tumor stage
was IIB in 7 patients, III in 4 and IV in 1.
There was no surgical mortality. The time of follow-up
ranged from 0.79 to 122.66 months with a median of
6.49 months. Figure 2 shows the cumulative survival rates
of 12 patients with pancreatic ASC with a median of 4.41
months, ranging from 1.12 to 22.42 months. Eleven of 12
patients with pancreatic ASC died in one year after surgery
with one-year survival rate of 8.3% (95% confidence
interval, 0.0–24). Figure 3 demonstrates cumulative sur-
vival rates of stage IIB pancreatic adenocarcinoma (n =
101) and ASC (n = 7) patients undergoing surgical resec-
tion. Patients with pancreatic ASC had shorter median
survival compared to those with adenocarcinoma (6.51
months vs. 9.76 months, p = 0.018).
Discussion
The first report of ASC is credited to Herxheimer in 1907
[8]. This admixed tumor has been seen more commonly
in other organ systems where adenocarcinomas are gener-
ally found, such as the stomach [9], intestine [10] and
uterus [11]. It has also been identified in the esophagus
[12], anus [13] and vagina [14] where squamous cell car-
cinomas predominate. In the present studies, the inci-
dence of pancreatic ASC was 1.9% (12/637), within the
range of 0.9 to 3.8% reported in the literatures [2-4]. The
histogenesis of pancreatic ASC remains unclear. There are
numerous possibilities that account for the presence of a
squamous element where adenocarcinoma is expected.
Four theories regarding the histogenesis of adenosqua-
mous carcinoma may be summarized as follows: adeno-
carcinoma transforming into squamous cell carcinoma;
Table 2: Details of tumor characteristics, management, and prognosis of 12 patients with pancreatic adenosquamous carcinoma.
Case Tumor location Size (cm) Operative method Intraoperative 
irradiation
Postoperative 
chemotherapy
Stage* (TNM) Survival (months)
1 Head 6 Biopsy, bypass ND ND III (T4N1M0) 4.04
2 Head 3.5 PD ND ND IIB (T2N1M0) 2.50
3 Body and tail 8 Biopsy, bypass ND ND IV (T4N1M1) 1.12
4 Head 6 Biospy 1,800 cGy ND III (T4N0M0) 22.42
5 Tail 8 Biopsy 2,000 cGy Gemcitabine III (T4N1M0) 5.42
6 Body 8 Biopsy, bypass ND Tegafur III (T4N1M0) 4.41
7 Head 3.8 PD ND Gemcitabine, 
Fluorouracil
IIB (T2N1M0) 6.84
8 Head 5.5 PD ND Gemcitabine IIB (T3N1M0) 6.51
9 Body 7 subtotal P, total G, S ND Tegafur, Uracil IIB (T3N1M0) 11.84
10 Tail 5 distal P, S ND ND IIB (T2N1M0) 10.82
11 Tail 8 distal P, total G, S ND Gemcitabine, Cisplatin IIB (T3N1M0) 3.68
12 Body and Tail 6.5 subtotal P, S ND Gemcitabine IIB (T3N1M0) 4.08
G, gastrectomy; ND, not done; P, pancreatectomy; PD, pancreaticoduodenectomy; S, splenectomy; *, clinical and pathological.
Histopathology in a patient with pancreatic tumor shows  glandular adenocarcinoma foci (black arrowheads) and nests  of squamous cell carcinoma (upper middle part), consistent  with adenosquamous carcinoma (Hematoxylin-Eosin stain,  original magnification ×100) Figure 1
Histopathology in a patient with pancreatic tumor 
shows glandular adenocarcinoma foci (black arrow-
heads) and nests of squamous cell carcinoma (upper 
middle part), consistent with adenosquamous carci-
noma (Hematoxylin-Eosin stain, original magnifica-
tion ×100).World Journal of Surgical Oncology 2008, 6:95 http://www.wjso.com/content/6/1/95
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bipotential undifferentiated cell origin; collision tumor;
and squamous metaplasia origin [5].
Madura et al. [1] reported that most patients with pancre-
atic ASC are males in their 60s and frequently located at
the head of the pancreas. Different from their findings,
more females were identified in our patients, and the
patient median age was 71 years. Moreover, our results
show that the tumor location was evenly distributed at the
pancreatic head, body, or tail. Symptoms of our patients
with pancreatic ASC were abdominal pain (92%), body
weight loss (83%), anorexia (42%) and jaundice (25%)
similar to those of pancreatic adenocarcinoma [15].
Accurate preoperative diagnosis of pancreatic ASC is made
with great difficulty since there are no investigations of its
defining characteristics in imaging studies that would dif-
ferentiate it from the more common pancreatic exocrine
neoplasm [1]. Nevertheless, studies have indicated that
cytological examination of pure pancreatic juice obtained
by endoscopic retrograde pancreatic juice aspiration is a
useful modality for the preoperative diagnosis [16].
Rahemtullah et al. [17] also reported that cytological fea-
tures derived from fine-aspiration biopsy are diagnostic of
pancreatic ASC. Furthermore, imaging studies by Nabae et
al. [15] showed that the presence of central necrosis in a
huge infiltrative pancreatic tumor is suggestive of the diag-
nosis of ASC. Moreover, a tumor might selectively take up
gallium 67 and be visualized by nuclear scanning which is
useful in detecting this rare pancreatic tumor [18]. In the
present studies, no patient had central necrosis at the pan-
creatic tumor on abdominal imaging studies indicating a
diagnosis of pancreatic ASC. Besides, the preoperative fine
needle biopsy of the tumor was performed in 1 patient,
which revealed adenocarcinoma.
As shown in table 2, 11 patients with pancreatic ASC
(92%) died within 12 months despite aggressive surgical
management along with intraoperative irradiation or
postoperative chemotherapy. The median cumulative sur-
vival of 12 patients was 4.92 months (Figure 2). Further-
more, median survival of 7 patients undergoing surgical
resection was 6.51 months. These results were similar to
that obtained by Madura et al. [1], who reported that 72
patients survived with an average age of 5.7 months,
regardless of whether or not surgical resection was per-
formed. To our surprise, 1 patient in our series who had
no lymph node involvement without undergoing surgical
resection and received intraoperative irradiation had a
survival of 22.42 months. No lymph node metastasis and
the potential benefit of intraoperative radiation therapy
might explain his long survival.
Once pancreatic ASC is identified either preoperatively or
intraoperatively, the choice of treatment becomes a com-
plex decision as survival is typically dismal [1]. In this
Cumulative survival rates of 12 patients with pancreatic adenosquamous carcinoma after surgery Figure 2
Cumulative survival rates of 12 patients with pancreatic adenosquamous carcinoma after surgery.World Journal of Surgical Oncology 2008, 6:95 http://www.wjso.com/content/6/1/95
Page 5 of 6
(page number not for citation purposes)
regard, although PD has been shown to be performed
with a very low mortality rate (<4%) in specialized high-
volume centers, the incidence of postoperative morbidity
can be as high as 30% to 40% [19,20]. Furthermore, a sig-
nificant high mortality rate (25%) has been reported in
the patient subgroup with significant preoperative comor-
bidities [20]. Thus, anesthesia risks and complications fol-
lowing major surgery in pancreatic ASC patients along
with severe medical diseases should be considered before
operation. Moreover, we observed that median survival of
patients (stage IIB) with pancreatic ASC undergoing surgi-
cal resection was 6.51 months, significantly shorter (p =
0.018) than patients with stage IIB pancreatic adenocarci-
noma receiving resection (median survival, 9.76 months;
Figure 3), suggesting more aggressive biology of pancre-
atic ASC than adenocarcinoma. Moreover, nodal metas-
tases were identified in 92% (11/12) of our patients,
which might reflect the disease entity tending to have
lymph node involvement and at least partly explained the
poor prognosis of this virulent tumor.
It should be noted that this study was based on a retro-
spective review of patients undergoing surgery. Pancreatic
malignancy patients who were not diagnosed as pancre-
atic ASC without tissue proof treated non-surgically were
not enrolled in this study. Whether surgical resection or
non-surgical management such as chemotherapy, radio-
therapy, chemo-radiotherapy or target therapy would pro-
vide survival benefits to patients with pancreatic ASC
remains unknown. More studies are necessary to confirm
this.
Conclusion
Pancreatic ASC is a rare pancreatic neoplasm subtype.
Abdominal pain and body weight loss are the two pre-
dominant symptoms. Distribution of ASC is even in the
pancreas, and the tumor size is big at the time of diagno-
sis. Pancreatic ASC tends to have nodal metastases and has
a dismal outcome despite surgical resection. In this lim-
ited case study, aggressive surgical management does not
appear effective in treating pancreatic ASC patients. Strat-
egies involving non-surgical treatment such as chemother-
apy, radiotherapy or target agents should be tested.
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